Competitive intelligence on
small-molecule drugs and
the 80,000 global patents
covering them

Start your free trial now

No commitment — No credit card required

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: Singulair

« Back to Dashboard

Summary for Tradename: Singulair

Patents:1
Applicants:1
NDAs:3
Suppliers: see list11

Pharmacology for Tradename: Singulair

Clinical Trials for: Singulair

The Effect of Montelukast in Patients With Chronic Cough and Bronchial Hyperreactivity
Status: Completed Condition: Cough; Bronchial Hyperreactivity

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Inhaled Montelukast (MK-0476) in Participants With Mild or Moderate Asthma (MK-0476-380 AM3)(COMPLETED)
Status: Completed Condition: Asthma

The Effect of Montelukast Treatment in Wheezy Infants
Status: Completed Condition: Lung Disease, Obstructive; Signs and Symptoms, Respiratory

Genotype Stratified Pharmacokinetic Study of Montelukast
Status: Recruiting Condition: Asthma

Effects of Leukotriene Modulator Montelukast on Cough Variant Asthma
Status: Recruiting Condition: Asthma

Montelukast in Very Low Birthweight Infants
Status: Completed Condition: Bronchopulmonary Dysplasia

Study of the Safety and Pharmacokinetics of Montelukast (MK-0476) in the Treatment of Japanese Pediatric Participants With Perennial Allergic Rhinitis (MK-0476-520)
Status: Completed Condition: Perennial Allergic Rhinitis

Singulair(R) In Asthma And Allergic Rhinitis (0476-383)
Status: Completed Condition: Asthma

Study of MK0476 in Adult Patients With Acute Asthma (0476-334)
Status: Completed Condition: Asthma

Effect of Addition of Single Dose of Oral Montelukast to Standard Treatment in Acute Asthma in Preschool Children.
Status: Completed Condition: Asthma; Acute Asthma

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck
SINGULAIR
montelukast sodium
TABLET, CHEWABLE;ORAL020830Feb 20, 1998RXYes<disabled><disabled>
Merck
SINGULAIR
montelukast sodium
GRANULE;ORAL021409Jul 26, 2002RXYes8,007,830<disabled>Y<disabled>
Merck
SINGULAIR
montelukast sodium
TABLET, CHEWABLE;ORAL020830Mar 3, 2000RXNo<disabled><disabled>
Merck
SINGULAIR
montelukast sodium
GRANULE;ORAL021409Jul 26, 2002RXYes<disabled><disabled>
Merck
SINGULAIR
montelukast sodium
TABLET;ORAL020829Feb 20, 1998RXYes<disabled><disabled>
This preview shows a limited data set
Subscribe for full access , or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: SINGULAIR

Drugname Dosage Strength RLD Submissiondate
montelukastTablets10 mgSingulair2/20/2007
montelukast sodiumChewable Tablets4 mg and 5 mgSingulair12/26/2006
« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc